These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. Christensen KV; Smith GP; Williamson DS Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412 [TBL] [Abstract][Full Text] [Related]
8. A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. Salašová A; Yokota C; Potěšil D; Zdráhal Z; Bryja V; Arenas E Mol Neurodegener; 2017 Jul; 12(1):54. PubMed ID: 28697798 [TBL] [Abstract][Full Text] [Related]
9. QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease. Sebastián-Pérez V; Martínez MJ; Gil C; Campillo NE; Martínez A; Ponzoni I J Integr Bioinform; 2019 Feb; 16(1):. PubMed ID: 30763264 [TBL] [Abstract][Full Text] [Related]
10. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease. Zhao Y; Dzamko N Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537 [TBL] [Abstract][Full Text] [Related]
12. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease. Wojewska DN; Kortholt A Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767 [TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. Ding X; Dai X; Long K; Peng C; Andreotti D; Bamborough P; Eatherton AJ; Edge C; Jandu KS; Nichols PL; Philps OJ; Stasi LP; Wan Z; Xiang JN; Dong K; Dossang P; Ho MH; Li Y; Mensah L; Guan X; Reith AD; Ren F Bioorg Med Chem Lett; 2017 Sep; 27(17):4034-4038. PubMed ID: 28774425 [TBL] [Abstract][Full Text] [Related]
14. Targeting LRRK2 in Parkinson's disease: an update on recent developments. Chan SL; Tan EK Expert Opin Ther Targets; 2017 Jun; 21(6):601-610. PubMed ID: 28443359 [TBL] [Abstract][Full Text] [Related]
15. Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. Gancia E; De Groot M; Burton B; Clark DE Bioorg Med Chem Lett; 2017 Jun; 27(11):2520-2527. PubMed ID: 28408230 [TBL] [Abstract][Full Text] [Related]
16. Development and biological evaluation of[ Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850 [TBL] [Abstract][Full Text] [Related]
17. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function. Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354 [TBL] [Abstract][Full Text] [Related]
19. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target. Chen J; Chen Y; Pu J Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795 [TBL] [Abstract][Full Text] [Related]